The glutamine story: where are we now?

被引:27
作者
Wischmeyer, Paul E.
机构
[1] Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO
[2] Department of Anesthesiology, University of Colorado Health Sciences Center, Campus Box B-113, Denver, CO 80262
关键词
critical care; heat shock protein; infection; inflammation; molecular mechanism; mortality; nutritional pharmacology;
D O I
10.1097/01.ccx.0000216582.87674.a4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review A recent editorial. proclaimed, 'Glutamine, a life saving nutrient, but why?' This review will assess if recent data support glutamine as a life-saving nutrient in critical illness, and, if so, utilize new understanding of gene-nutrient interactions to address potential mechanisms by which glutamine may be 'life-saving'. Recent findings Updated meta-analysis data reveal that glutamine appears to exert a beneficial effect on mortality in critical illness. The questions remaining to be answered regard in what settings and via what method of administration does this phamaconutrient show optimal benefit? It is likely that examination of molecular mechanisms by which glutamine functions will lead to an understanding of how best to utilize glutamine as a pharmacologic agent. Recent laboratory data reveal that these mechanisms include tissue protection, attenuation of inflammation, improved tissue metabolic function, and attenuation of oxidant stress. Summary Glutamine may be potentially 'life-saving' in critical illness, particularly when administered in doses greater then 0.3 g/kg/day. Present data indicate that,glutamine functions as a 'stress signaling molecule' following illness/injury and thus, needs to be given as a pharmacologic agent, rather then as nutritional replacement. Presently, multicenter clinical trials utilizing glutamine as a drug, independent of nutritional needs, are indicated.
引用
收藏
页码:142 / 148
页数:7
相关论文
共 47 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P31
  • [3] A profile of combat injury
    Champion, HR
    Bellamy, RF
    Roberts, CP
    Leppaniemi, A
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2003, 54 (05): : S13 - S19
  • [4] Modulating effect of glutamine on IL-1β-induced cytokine production by human gut
    Coëffier, M
    Marion, R
    Ducrotté, P
    Déchelotte, P
    [J]. CLINICAL NUTRITION, 2003, 22 (04) : 407 - 413
  • [5] Molecular mechanisms of glutamine action
    Curi, R
    Lagranha, CJ
    Doi, SQ
    Sellitti, DF
    Procopio, J
    Pithon-Curi, TC
    Corless, M
    Newsholme, P
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 204 (02) : 392 - 401
  • [6] Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine
    De-Souza, DA
    Greene, LJ
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (05) : 1125 - 1135
  • [7] Glutamine and heat shock proteins: One more approach to lung injury
    Deutschman, CS
    Levy, RJ
    Weiss, YG
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (06) : 1422 - 1424
  • [8] Glutamine inhibits cytokine-induced apoptosis in human colonic epithelial cells via the pyrimidine pathway
    Evans, ME
    Jones, DP
    Ziegler, TR
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2005, 289 (03): : G388 - G396
  • [9] Cytopathic hypoxia - Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration?
    Fink, MP
    [J]. CRITICAL CARE CLINICS, 2002, 18 (01) : 165 - +
  • [10] FUCHS BC, 2005, J SURG RES 0907